Evaxion A (EVAX) Other Non-Current Liabilities (2021 - 2025)
Evaxion A's (EVAX) quarterly Other Non-Current Liabilities came in at $158000.0 in Q4 2025, up 12.06% YoY from $141000.0 in Q4 2024, and little changed on a QoQ basis from $158000.0 in Q2 2025.
Evaxion A (EVAX) Other Non-Current Liabilities (2021 - 2025) Analysis & Trends
Evaxion A (EVAX) has 5 years of Other Non-Current Liabilities data on file, last reported at $158000.0 in Q4 2025.
- Quarterly Other Non-Current Liabilities rose 12.06% year-over-year to $158000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $158000.0 (up 12.06% YoY) and the FY2025 annual result came in at $158000.0, up 12.06% from the prior year.
- Other Non-Current Liabilities was little changed at $158000.0 in Q4 2025, from $158000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $573000.0 in Q4 2022 to a low of $52000.0 in Q1 2021.
- A 5-year average of $167461.5 and a median of $149000.0 in 2023 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2022 — Other Non-Current Liabilities soared 274.51% — and 2023, when it slumped 74.0%.
- Tracing EVAX's Other Non-Current Liabilities over 5 years: stood at $153000.0 in 2021, then soared by 274.51% to $573000.0 in 2022, then tumbled by 74.0% to $149000.0 in 2023, then retreated by 5.37% to $141000.0 in 2024, then grew by 12.06% to $158000.0 in 2025.
- The last three Other Non-Current Liabilities figures came in at $158000.0 (Q4 2025), $158000.0 (Q2 2025), and $141000.0 (Q4 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Evaxion A | 27.61 Mn | 27.61 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 158,000.00 |
| Jun 30, 2025 | 158,000.00 |
| Dec 31, 2024 | 141,000.00 |
| Jun 30, 2024 | 145,000.00 |
| Dec 31, 2023 | 149,000.00 |
| Jun 30, 2023 | 147,000.00 |
| Dec 31, 2022 | 573,000.00 |
| Jun 30, 2022 | 141,000.00 |
| Mar 31, 2022 | 150,000.00 |
| Dec 31, 2021 | 153,000.00 |
| Sep 30, 2021 | 157,000.00 |
| Jun 30, 2021 | 53,000.00 |
| Mar 31, 2021 | 52,000.00 |